Skip to main content
Clinical Trials/NCT02837952
NCT02837952
Completed
Phase 3

A Phase 3, Double-blind, Randomized Safety And Efficacy Study Comparing Multiple Administrations Of Ibu 250 Mg/Apap 500 Mg (Administered As Two Tablets Of Ibu/Apap 125 Mg/250 Mg) To Placebo In The Treatment Of Post Surgical Dental Pain In Adult Subjects

Pfizer1 site in 1 country123 target enrollmentAugust 31, 2016

Overview

Phase
Phase 3
Intervention
FDC IBU/APAP 250 mg/500 mg
Conditions
Pain
Sponsor
Pfizer
Enrollment
123
Locations
1
Primary Endpoint
Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 24 Hours Post-dose (SPID11 [0-24])
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This study is being conducted to determine the overall analgesic efficacy and safety of a fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation compared to placebo in subjects who are experiencing post operative pain following surgical extraction of 3 or more third molar teeth. A review of any reported adverse events will also be completed.

Registry
clinicaltrials.gov
Start Date
August 31, 2016
End Date
February 1, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pfizer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg

FDC IBU/APAP 250 mg/500 mg

Intervention: FDC IBU/APAP 250 mg/500 mg

Placebo

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 24 Hours Post-dose (SPID11 [0-24])

Time Frame: 0 to 24 hours post dose

Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 \[0-24\]: Time-weighted sum of Pain Intensity Difference (PID) scores over 24 hours. SPID11 score range was -120 (worst score) to 240 (best score) for SPID 0-24. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).

Secondary Outcomes

  • Time-weighted Sum of Pain Intensity Difference Score on 11-Point Numerical Scale (SPID11) From 0 to 8, 6 to 8, 0 to 16, 8 to 16 and 0 to 48 Hours Post-dose(0 to 8 hours, 6 to 8 hours, 0 to 16 hours, 8 to 16 hours and 0 to 48 hours post dose)
  • Duration of Relief After First Dose(Up to 8 hours after first dose)
  • Time to Onset of "Meaningful" Pain Relief After First Dose(Up to 8 hours after first dose)

Study Sites (1)

Loading locations...

Similar Trials